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1. Introduction
Cardiovascular disease (CVD) is a substantial and growing problem in most of the developing
regions of the world. Evidence from experimental, clinical and epidemiological studies has
unequivocally pointed to oxidative stress as the key culprit in the pathogenesis of CVD [1, 2].
CVD continues to remain a concern in developed countries and is a growing health concern
worldwide. Although death rates from CVD have decreased in many countries due to
advances in the field of medicine, the prevalence of CVD risk factors continues to increase.
Diet is a centrally important, modifiable risk factor in the prevention of CVD [221-224].
The protection offered by foods is probably mediated through multiple beneficial nutrients
contained in these foods, including mono- and polyunsaturated fatty acids, antioxidant
vitamins, minerals, phytochemicals, fibre and plant protein. In dietary practice, healthy plant-
based diets do not necessarily have to be low in fat. Instead, these diets may include unsatu‐
rated fats as the predominant form of dietary fat (e.g., fats from natural vegetable oils and
nuts).
Consistent evidence suggests that diets rich in fruit and vegetables and other plant foods are
associated with moderately lower overall mortality rates and lower death rates from chronic
diseases including CVD [3- 6]. The ‘antioxidant hypothesis’ proposes that vitamin C, vitamin
E, carotenoids and other antioxidant nutrients offer protection against CVD by decreasing
oxidative damage [7-9]. As evidence began to mount from animal studies and human epide‐
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miological studies on the potential protective effects of antioxidants, excitement in both the
lay and medical communities also began to increase.
There has been a global increase in the use of medicinal plants that contain significant amounts
of antioxidant-rich oils, offering multiple health benefits with fewer side effects compared to
their synthetic counterparts. The idea is that natural compounds, if taken in supplement form,
may offer a broad and inexpensive means of decreasing the risk for CVD. Natural products,
such as vegetable oils and nuts, may be viewed as a cocktail of active ingredients that often
have a synergistic effect on health. The (n-3) PUFAs have been shown in epidemiological and
clinical trials to reduce the incidence of CVD. Large-scale epidemiological studies suggest that
individuals at risk of coronary heart disease (CHD) benefit from the consumption of plant and
marine derived (n-3) PUFAs, although the ideal intake is presently unclear. Overall, in view
of the prevalence of CHD, consumption of (n-3) PUFA oils should be considered as a useful
complementary option for the amelioration of CVD. Several researchers have shown encour‐
aging findings on the protective effects of some vegetable oils and nuts. However, more
research needs to be done with regards to the nutrients in these vegetable oils and nuts to
elucidate the protective effects against CVD progression. This chapter focuses on the beneficial
roles of antioxidant-rich vegetable oils and nuts in the management of CVD, their mechanisms
of action and future prospects.
The term “cardiovascular disease (CVD)” encompasses the major clinical end-points related
to the heart and vascular system, including ischaemic myocardium (heart failure and angina),
myocardial infarction (heart attack), cerebrovascular disease (stroke), high blood pressure
(hypertension), peripheral arterial disease (ischaemia of the limbs), arrhythmias, congenital
heart disease and rheumatic heart disease. The facts are unequivocal and disturbing; CVD is
the leading cause of death worldwide [10-12].
Chronic diseases are disorders with a long duration and generally slow progression. They
comprise  four  major  non-communicable  diseases  (NCDs)  as  listed by the  World Health
Organization (WHO), namely CVD, cancer, chronic respiratory disease and diabetes [13], which
are now reaching epidemic proportions in low- and middle-income countries (LIMIC) of the
world [14-18]. NCDs constitute the major global health burden of the 21st century [19-20] without
discriminating among age groups [21]. Chronic diseases are implicated in 35 million deaths
annually worldwide and a large portion of these deaths occurs due to CVD in LIMIC [22].
There is a rising epidemic of NCDs in sub-Saharan Africa (SSA). However, as in other LIMICs,
individuals in SSA suffer from the dual burdens of infectious disease and NCDs [22, 23].
Walker and colleagues [24] reported that SSA continues to suffer under the weight of infectious
diseases such as HIV and malaria, as well as high rates of undernutrition. Facing these issues
in conjunction with the chronic diseases that accompany high rates of overnutrition is a
daunting task [25] for the health burden in Africa. SSA has a disproportionate burden of both
infectious and chronic diseases compared with other parts of the world [26]. South Africa (SA)
is a country of great diversity extending from highly industrialized cities with an urban
advanced-economy lifestyle to remote rural areas with more traditional lifestyles. SA, like
many SSA countries, is not immune to the NCD epidemic accompanied by the continued
burden of undernutrition. In SA, approximately 28% of deaths annually are attributed to
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infectious diseases, while NCDs account for 25% of the lives lost [27]. The burden of diseases
related to NCDs is predicted to rise substantially in SA over the next decade if necessary
measures are not in place to combat the trend [28]. WHO estimates the burden from NCDs in
SA to be two to three times higher than that in developed countries [13].
Approximately 35-65% of all deaths worldwide occur due to CVDs and death rates exceed
these estimated figures owing to malnutrition and infections [29, 30]. CVDs and their risk
factors are increasing in SSA [17, 31] with a high prevalence of ischaemic heart disease among
men in their sixties followed by women of the same age group [17]. The common potential risk
factors for NCDs are tobacco use, physical inactivity and an unhealthy diet, which all lead to
CVD, diabetes and cancer [32, 33]. This burgeoning epidemic of NCDs has many root causes.
Additional perpetuators of these epidemics are globalization and urbanization [34-37] with
abdominal obesity contributing significantly to CVD in the SSA region [38]. Compelling
evidence demonstrates a rise in mortality and morbidity from the NCDs in all strata of South
African society. Leeder and colleagues [39] estimated that even without changes in the risk
factor profile or the mortality rates from CVD, the demographic changes will result in a
doubling of the number of cardiovascular deaths in SA by 2040. Chronic diseases such as CVD,
obesity and diabetes have therefore become at least as important as infectious disease.
In summary, CVD is a substantial and growing problem in most of the developing regions of
the world. The burden of NCD on the African continent and in SA in particular continues to
demonstrate the potential for a sustained rise. A significant investment in the health care
system and in particular the primary health care system is therefore justified. Further innova‐
tive strategies and plans are needed to address the determinants of this disease burden.
However, indications still point to the paucity of community-based studies aimed at investi‐
gating NCD prevalence, incidence and risk factors. Consistent evidence suggests that diets
rich in fruit and vegetables and other plant foods are associated with moderately lower overall
mortality rates and lower death rates from chronic diseases including CVD [3-6]. The ‘antiox‐
idant hypothesis’ proposes that carotenoids, polyphenols, vitamin C, vitamin E and other
antioxidant nutrients afford protection against CVD by decreasing oxidative damage [7-9]. As
the evidence began to mount from animal studies and human epidemiologic studies on
potential protective effects of antioxidants, excitement in both the lay and medical communi‐
ties also began to increase. The idea that natural compounds, if taken in supplement form, may
offer a broad and inexpensive means of decreasing the risk for CVD and other age-related
diseases is a very attractive hypothesis. Enthusiasm has grown to the point where people
around the globe have become aware of the need to consume a diet with a high content of fruit
and vegetables.
Indeed, evidence from experimental, clinical and epidemiologic studies has unequivocally
pointed to oxidative stress as the key culprit in the pathogenesis of CVD [1, 2, 40, 41]. CVD
continues to remain a significant problem in developed countries and is a growing health
concern worldwide. Although death rates from CVD have decreased in many countries, due
to advances in the field of medicine, the prevalence of CVD risk factors continues to increase.
Diet is a centrally important, modifiable risk factor in the prevention of CVD [221-224].
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2. Can vegetable oils and nuts be the natural solution for CVD?
Oxidative stress is common in many clinically important cardiac disorders, including ischae‐
mia/reperfusion (I/R) injury, diabetes and hypertensive heart disease [42-46]. Several animal
models suggest that when endogenous anti-oxidant systems are compromised, as is the case
under oxidative stress conditions, exogenous antioxidant supplementation can be used for
preventive and/or therapeutic intervention of CVD [42, 43, 47-49].
2.1. Composition and health benefits of vegetable oils
2.1.1. Dietary fats
Fats are the most concentrated form of energy for the body. They also aid in the absorption of
fat-soluble vitamins (A, D, E and K) and other fat-soluble biologically active components [50].
Chemically, most of the fats in foods are triglycerides, made up of a unit of glycerol combined
with free fatty acids, each of which may be the same or different. Other dietary fats include
phospholipids, phytosterols and lipoproteins associated with cholesterol [50-52]. A balanced
diet, including oils and fats that supply energy and essential fatty acids is needed for good
health.
The different types of fatty acids are the most important characteristics of dietary fats.
According to the degree of unsaturation (double bonds and hydrogen content), fatty acids are
largely classified into three major types: saturated fatty acids, monounsaturated fatty acids
(MUFA) and polyunsaturated fatty acids (PUFA). A fourth form, the trans fatty acids, are
mainly produced by partial hydrogenation of polyunsaturated oils in food processing but also
occur naturally in animal foods in small amounts [53].
Fatty acids consist of a hydrocarbon chain with a hydrophobic methyl group at one end and
a hydrophilic carboxyl group at the other end. Greek letters (α, β, γ, ω) have been used to
identify the location of the double bonds in fatty acids. The “alpha” carbon is the carbon closest
to the carboxyl group. The methyl group of the molecule is also referred to as the omega end
and the terminal carboxyl group is located at the delta end. Current chemical numerical terms
number the carbon chain form one to “n”, with n being the last carbon at the methyl end. The
terms “n” and “omega” are synonymous [54].
2.1.2. Saturated fat
Saturated fatty acids contain no double bond; they are fully saturated with hydrogen. The main
saturated fatty acids are lauric acid (C12:0), myristic acid (C14:0), palmitic acid (C16:0) and
stearic acid (C18:0). Saturated fats are found in animal-based products, such as milk, cream,
butter and cheese, meat from most land animals, palm oil and coconut oil, as well as manu‐
factured products made from these, such as pies, biscuits, cakes and pastries [55].
2.1.3. Monounsaturated fat (MUFA)
MUFAs are predominant in vegetable oils, such as olive oil, canola oil and peanut oil and are
also found in high proportions in animal fats [56]. Much of the interest in the role of MUFA in
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the prevention of coronary heart disease (CHD) stems from the observed beneficial effects of
the Mediterranean diet [57], which includes high consumption of olive oil. MUFAs are less
susceptible to oxidation when compared to PUFAs. This in turn leads to increased availability
of antioxidants in the active form and better stability of olive oil [58-61]. Olive oil also contains
some antioxidant micronutrients, namely polyphenols and squalene [58, 62-64]. The main
MUFA in the human diet is oleic acid (C18:1n-9), which has one double bond. MUFA intake
has been associated with a slight cardioprotective effect [65]. MUFAs are known to have a
beneficial effect on the serum lipid profile and thus decrease the risk of CVD [66-68]. Further‐
more, these fatty acids are stable in oxidative stress conditions and are less likely to react with
reactive oxygen species (ROS) when compared with PUFA [58-59]. However, studies reporting
associations between dietary intake of MUFAs and CHD risk have been inconclusive [69-71].
2.1.4. Polyunsaturated fat (PUFA)
PUFAs are naturally occurring endogenous substances, present in almost all tissues and are
essential components of all mammalian cells. They are essential for survival and cannot be
synthesized in the body. Hence, they have to be obtained in our diet and are therefore essential
[54, 72]. There are two types of naturally occurring PUFAs in the body, the (n-6) PUFAs derived
from linoleic acid (LA, C18:2) and the (n-3) PUFAs derived from α-linolenic acid (ALA, C18:3).
They are categorized depending on the location of their first double bond: (n-3) PUFAs have
their first double bond located at the third carbon molecule and (n-6) PUFAs at the sixth. Both
of these two forms of PUFAs are metabolized by the same set of enzymes as their respective
long-chain metabolites [73]. The differences between (n-3) and (n-6) PUFAs are shown in Table
1 below.
Vegetable oils are the predominant sources of alpha linolenic acid (ALA). ALA is found in
legumes, flax seeds, walnuts, pinto beans, soybeans and spinach [74]. Dietary intake of ALA
among Western adults is typically in the range of 0.5–2g/d [75]. The (n-6) PUFA is the main
PUFA in most Western diets and is typically consumed in greater amounts than ALA [75, 76].
The evidence for a beneficial role of dietary (n-6) PUFAs is less convincing and for the purpose
of this chapter we will focus on the (n-3) PUFA. The three main forms of (n-3) PUFAs are ALA,
eicosapentaenoic acid (EPA, C20:5 n-3) and docosahexaenoic acid (DHA, C22:6 n-3) [77], with
ALA being the simplest form. The (n-3) PUFAs are a family of biologically active fatty acids.
The simplest member of this family, ALA, can be converted to the more biologically active and
very long-chain (n-3) PUFAs; EPA and DHA. This process, as shown in Figure 1, occurs by a
series of desaturation and elongation reactions, with stearidonic acid being an intermediate in
the pathway [54, 75, 78].
Research has shown that long-chain (n-3) PUFAs protect against CVD [77, 79-82]. The cardi‐
oprotective effects of (n-3) PUFAs have long been recognized. Epidemiologic data suggest that
(n-3) PUFAs derived from fish oil reduce CVD. Fish oil is a rich source of EPA (C20:5 n-3) and
DHA (C22:6 n-3) (Table 1) [67, 83, 84]. The cardioprotective roles of these two forms of (n-3)
PUFA are extensively reviewed by Bester and co-workers [48]. Fish oil may also reduce
mortality after a cardiovascular incident, as it plays a role in reducing potentially fatal
arrhythmias ([85-87]. There are several prospective studies relating the use of fish or the intake
Dietary Antioxidant Properties of Vegetable Oils and Nuts – The Race Against Cardiovascular Disease Progression
http://dx.doi.org/10.5772/57184
213
of long-chain (n-3) PUFAs to lower risk of CVD [88, 89]. Long chain (n-3) PUFAs have several
beneficial cardiovascular properties, including antiatherothrombotic, antiarrhythmic, anti-
inflammatory, antihypertensive and triglyceride lowering [81, 90, 91]. In summary, studies
investigating the dietary roles of fatty acids demonstrate that dietary supplementation with
(n-3) PUFAs decreases cardiac deaths, nonfatal cardiovascular events and all-cause mortality.
These benefits are most apparent in high-risk patients. (n-3) PUFA supplementation appears
to confer additional benefits in patients eating a Mediterranean diet.
The original observation is from almost 57 years ago, when Hugh M. Sinclair [92] published
his observations on the negative effects of essential fatty acid deficiency on CVD. He strength‐
ened his hypothesis by noting the low mortality rate from CHD (coronary heart disease) in
Greenland Eskimos, a population consuming a high fat diet, but rich in (n-3) PUFAs [92].
Clinical studies suggest that (n-3) PUFAs reduce mortality from coronary heart disease and
the rate of sudden cardiac death [92-95]. Significant antiarrhythmic effects of (n-3) PUFAs were
observed in some but not all human studies on atrial fibrillation [96, 97]. In addition, animal
studies show strong antiarrhythmic effects of (n-3) PUFAs [98-102].
 (n-3) PUFA (n-6) PUFA
Molecular
structure
First double-bond on the third carbon
counting from the methyl end (the
“nth” carbon)
First double-bond on the sixth carbon counting from the
methyl end (the “nth” carbon)
Types α-Linolenic acid (ALA) [C18:3]
Eicosapentaenoic acid (EPA) [C20:5]
Docosahexaenoic acid (DHA) [C22:6]
Linoleic acids (LA) [C18:2]
Arachidonic acid (AA) [C20:4]
Food sources Flaxseed oil (ALA)
Canola oil (ALA)
Soybean oil (ALA)
Oily fish (EPA/DHA)
Fish oil capsules (EPA/DHA)
Corn oil(LA)
Soybean oil (LA)
Sunflower oil (LA)
Poultry (AA)
Meats (AA)
Table 1. Molecular structure, types and food sources of (n-3) and (n-6) PUFAs.
Long-chain (n-3) PUFAs are important constituents of all cell membranes and confer on
membranes properties of fluidity and thus, determine and influence the behaviour of mem‐
brane-bound enzymes and receptors [103-107]. These PUFAs are found in abundance in the
myocardium, retina, brain and spermatozoa, and are essential for the proper functioning of
these tissues and growth, being important modulators of many physiological processes. The
fact that these tissues have developed the cellular machinery to preferentially incorporate these
minor dietary components into their membranes suggests that these PUFAs play a role in the
proper function of the cell [108-110].
The fatty acid composition of myocardial membrane phospholipids, in particular, is sensitive
to the type of fatty acid consumed in the diet. Studies show that indeed the myocardium and
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myocardial membrane phospholipids are rich in (n-3) PUFAs after fish oil consumption [111,
112]. Diet-induced changes in the PUFA composition of a cell membrane have an impact on
the cell’s function, partly because these fatty acids represent a reservoir of molecules that
perform important signalling roles within and between cells. In particular, dietary (n-3) PUFAs
compete with dietary (n-6) PUFAs for incorporation into all cell membranes [113,114]. (n-3)
PUFAs modulate the expression of adhesion proteins such as selectins [115] and exert an effect
by modulating the intracellular signalling pathways associated with the control of transcrip‐
tion factors (e.g., nuclear factor-κB) and gene transcription [116,117]. Research has shown that
enrichment of monocyte membranes with (n-3) PUFAs results in the synthesis and secretion
Figure 1. The biosynthesis of (n-3) PUFA.
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of reduced quantities of cytokines (e.g., tumour necrosis factor-α, interleukin-1β) that are
involved in the amplification of the inflammatory response [117,118]. Therefore, at a cellular
level, (n-3) PUFAs from fish oils can directly or indirectly modulate a number of cellular
activities associated with inflammation.
2.1.5. Polyphenols
Polyphenols constitute one of the most numerous and ubiquitously distributed groups of plant
secondary metabolites, with more than 8000 phenolic structures currently known. Natural
polyphenols can range from simple molecules (phenolic acids, phenylpropanoids, and
flavonoids) to highly polymerised compounds (lignins, melanins, tannins), with flavonoids
representing the most common and widely distributed sub-group [119]. These secondary plant
metabolites are known to have potential antioxidant activity and radical scavenging capacity
[120-124]. Polyphenols are gaining increased importance due to their beneficial effects on
health. Flavonoids are the most abundant polyphenols in our diets. They can be divided into
several classes according to the degree of oxidation of the oxygen heterocycle: flavones,
flavonols, isoflavones, anthocyanins, flavanols, proanthocyanidins and flavanones [125]. A
complication of the epidemiological observations regarding members of the flavonoid family
is that subtle differences in their chemical structures can translate into marked differences in
their absorption, metabolism and bioactivities [126]. South African herbal teas, rooibos
(Aspalathus linearis) and honeybush (Cyclopia ssp.) are currently gaining popularity worldwide
[127, 128], owing to their anti-oxidant, anti-cancer and anti-mutagenic properties [129-131].
Rooibos is a herbal tea made from the leaves and stems of the indigenous South African plant,
Aspalathus linearis (Brum.f) Dahlg. (family Fabaceae; tribe Crotalarieae) [132,133]. Research has
demonstrated that this herbal tea is rich in flavonoids [127, 134]. Animal studies that have
investigated the cardioprotective effects of natural or synthetic flavonoids have focused mainly
on the acute pharmacological activity of these compounds. For example, in vivo studies using
animal models have reported acute cardioprotection obtained from intravenous injections of
natural or synthetic flavonoids [135,136].
2.1.6. Vitamin E
Natural vitamin E is composed of eight chemical compounds: α-, β-, γ- and δ-tocopherols and
their corresponding tocotrienols. α-Tocopherol is the most active form of vitamin E in vitro.
The tocopherols are saturated forms of vitamin E, whereas the tocotrienols are unsaturated
and have an isoprenoid side chain. Tocopherols possess a chromanol ring and a 15-carbon tail.
The presence of three trans double bonds in the tail distinguishes tocopherols from tocotrienols
[137-139]. This may account for the differences in their efficacy and potency in vitro and in
vivo [140,141].
Red palm oil (RPO) is a rich source of vitamin E. It contains 560–1000 parts per million of
vitamin E, of which approximately 18–22% are tocopherols and 78–82% tocotrienols [142-144].
RPO has been shown to offer protection against I/R injury [42, 43, 47, 48] leading to a reduction
in oxidative stress [145]. It has also been suggested that palm oil may have some anti-arrhyth‐
mogenic effects, which may reduce sudden death after ischaemic incidents [146].
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Of all the vegetable oils, RPO has the highest content of tocotrienols with γ-tocotrienol the
most abundant. This form of vitamin E has been demonstrated to reduce cholesterol produc‐
tion and platelet aggregation [147-151]. RPO may also exert a neutral or positive effect on the
serum lipid profile through the effects of its fatty acid composition and tocotrienols [152-155].
Investigations into vitamin E showed that tocotrienols are more potent than tocopherols as
antioxidants. The tocotrienols present in palm oil have been shown to offer protection from
myocardial I/R injury in an isolated perfused rat heart model [156, 157]. Animal studies with
tocopherols and tocotrienols that investigate these compounds’ potential against chronic
diseases are extensively reviewed by Aggarwal and co-workers [158]. These authors argue that
the evidence overwhelmingly suggests that tocotrienols may be superior in their biological
properties than tocopherols and that their anti-inflammatory and antioxidant activities could
prevent CVD among other chronic diseases.
2.1.7. Carotenoids
Carotenoids are nature’s most widespread pigments, well known for their orange-red to
yellow colours, which they impart to many fruits and vegetables. These fat-soluble phyto‐
chemicals have also received substantial attention because of their provitamin A and antioxi‐
dant roles [159]. Carotenoids are polyenoic terpenoids with conjugated trans double bonds.
They include carotenes (β-carotene and lycopene), which are polyene hydrocarbons and
xanthophylls (lutein, zeaxanthin, capsanthin, canthaxanthin, astaxanthin and violaxanthin)
that have oxygen in the form of hydroxy, oxo, or epoxy groups [160]. The majority of the 600
carotenoids found in nature are 40 carbons in length and may be pure hydrocarbons, called
carotenes, or possess oxygenated functional groups, in which case they are called xanthophylls
[161]. The long-chain conjugated polyene structure accounts for the ability of these compounds
to absorb visible light, but also makes them quite susceptible to oxidation. This latter property
is closely related to their ability to act as antioxidants [162].
The properties and therefore functions of a carotenoid molecule are primarily dependent upon
its structure and hence its chemistry [163]. In particular, the conjugated C = C double bond
system is associated with energy transfer reactions, such as those found in photosynthesis
[164]. In human plasma and tissues, several carotenoids have been well characterized includ‐
ing cyclic (such as β-carotene and α-carotene) and acyclic carotenes (such as lycopene and
phytoene), together with a number of xanthophylls (such as zeaxanthin, lutein and beta-
cryptoxanthin), all of which can be directly derived from dietary sources [165]. Carotenoids
have generated considerable interest as several studies have suggested an inverse association
between the dietary intake of carotenoids and the risk for CVD [166, 167]. Conversely proox‐
idant roles of these phytochemicals have also been reported [168-170].
2.1.8. Possible mechanism(s) of action
As mentioned earlier, RPO supplementation does offer protection against myocardial I/R
injury via several suggested mechanisms. Amongst the proposed mechanisms are the NO–
cyclic GMP pathway, phosphorylation of mitogen-activated protein kinases and scavenging
of deleterious reactive oxygen species by RPO [42, 43, 47, 48].
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Investigations concerning (n-3) PUFAs show that these forms of essential fatty acids reduce
the risk of sudden cardiac death as well as fatal and nonfatal myocardial infarction [171-173].
A number of mechanisms have been implicated in the protective effects of (n-3) PUFAs [174,
175]. The (n-3) PUFAs have been demonstrated as altering the transcription of specific genes.
These effects are mediated by a variety of mechanisms that involve indirect (i.e., by eicosa‐
noids, hormones) and direct nuclear effects on genes. The PUFAs (i.e., both (n-3) and (n-6)
PUFAs) modulate the expression of genes involved in lipogenesis, glycolysis, production of
glucose transporters, inflammatory mediators, early response genes and genes for cell
adhesion molecules [176, 177].
The primary source of MUFA that lowers cholesterol levels is olive oil [178, 179]. It is evident
that olive oil, due to its micronutrient content and fatty acid composition, can play a vital role
in maintaining beneficial serum lipid profiles. Together with its ability to reduce systemic
oxidative stress, blood pressure and inflammation, it has become an appropriate dietary
supplement for lowering the risk of CHD.
2.2. Composition and health benefits of nuts
Nuts are highly nutritious and of prime importance for people in several regions in Asia and
Africa. Most nuts contain a great deal of fat (e.g., pecan 70%, macadamia nut 66%, Brazil nut
65%, walnut 60%, almonds 55% and peanut butter 55%). Most have a good protein content (in
the 10–30% range) and only a few have a very high starch content [180]. Many nuts have also
been identified as especially rich in antioxidants [181, 182]. Nuts therefore constitute one of
the most nutritionally concentrated kinds of food available. Most nuts, left in their shell, have
a remarkably long shelf life and can conveniently be stored for winter use [183]. Nuts are foods
rich in fat, ranging from 46% in cashews and pistachios to 76% in macadamia nuts and provide
20–30 kJ/g per nut. Despite their high fat content, they are not harmful because they contain a
low proportion (4–16%) of saturated fatty acids. Nearly one half of the fat content of nuts
consists of unsaturated fatty acids, including both mono- (oleic acid) and poly- (linoleic and
α-linolenic acid) unsaturated fatty acids (MUFA and PUFA respectively). The fatty fraction of
nuts also contains plant sterols with anti-oxidants [184] and cholesterol-lowering effects [185].
Nuts are also rich sources of other bioactive macronutrients, such as protein (25% of energy)
and dietary fibre, which ranges from 4 to 11g/100 g and in standard servings provide 5–10%
of daily fibre requirements. They also contain significant micronutrients (Table 2), among them
folate [185] antioxidant vitamins (e.g., tocopherols) and phenolic compounds [183].
By virtue of their unique composition, nuts are likely to benefit modern cardiovascular risk
biomarkers, such as LDL oxidizability, soluble inflammatory molecules and endothelial
dysfunction. The complex pathophysiology of atherosclerotic disease has evolved beyond the
accumulation of cholesterol in the arterial wall. A series of circulating, functional, structural
and genomic biological markers that reflect arterial vulnerability have been proposed as
potential novel risk factors for the development of CVD (Vasan, 2006). Among them, bio‐
markers for oxidation [186], inflammation [187] and endothelial dysfunction [188] have
received increasing attention.
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Studies had shown that whole, unprocessed and unpeeled nuts have a unique composition
that consists of important macro- and micronutrients, which give nuts their multiple beneficial
effects on cardiovascular outcomes [189-192]. Most nut constituents have shown beneficial
effects when clinically tested, in isolation or as part of enriched foods, for effects on diverse
cardiovascular outcomes, including novel risk markers [189-192].
2.2.1. Antioxidant effects
Nuts are important sources of tocopherols and phenolic antioxidants, which protect against
LDL oxidation [183]. Walnuts have been shown to contain substantial amounts of melatonin,
which contributed to a significant antioxidant effect in an experimental rat model [193]. In
addition, a substantial fraction of nut fat comes from MUFAs, which are not susceptible to
oxidation. The PUFAs are contained mainly in walnuts and are more susceptible to oxidation.
However, nuts are a rich source of many antioxidants, which protect the PUFA in vivo against
oxidative modification [194].
2.2.2. Anti-inflammatory effects
Plasma high-sensitivity CRP, an accepted measure for systemic low-grade inflammation, was
a secondary outcome in several controlled nut feeding trials conducted in hypercholesterole‐
mic subjects with almonds [195-198] or walnuts [197, 199]. Some of them have demonstrated
a CRP-lowering effect [196, 197, 198]. Zhao et al., who used walnuts and walnut oil to enrich
the diet in PUFA and especially ALA, showed a decrease in inflammatory markers [197] and
proinflammatory cytokine production by mononuclear cells [197].
2.2.3. Effects on endothelial function
Endothelial dysfunction is a critical event in atherogenesis and is implicated both in early
disease  and  in  advanced  atherosclerosis  [201].  Short-term  feeding  studies  have  shown
consistently that diets rich in saturated fatty acids impair endothelial  function [181,  202,
203] and that even a single fatty meal rich in saturated fatty acids is followed by transi‐
ent endothelial dysfunction [204, 205]. These detrimental effects can be counteracted by the
Table 2. Composition of Nuts (data from the US department of agriculture nutrient database)
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administration of PUFA and other nutrients contained in nuts, such as antioxidant vitamins
and  arginine  [179].  Another  feeding  trial  showed  that,  compared  with  an  isoenergetic
Mediterranean diet with similar saturated fatty acid content, a walnut diet attenuated the
endothelial dysfunction associated with hypercholesterolemia [199]. Moreover, changes in
circulating levels  of  cellular  adhesion molecules  critical  to  leukocyte  recruitment  on the
arterial wall also reflect endothelial dysfunction [201]. Several studies have shown that diets
enriched with ALA from walnuts [197, 199, 206] reduce endothelial activation as assessed
by  decreased  plasma  cellular  adhesion  molecules.  Walnut  feeding  also  reduced  the
expression of endothelin-1, a potent endothelial activator in an animal model of accelerat‐
ed atherosclerosis [207].
2.2.4. Effects on body weight changes
As the interest in incorporating nuts into the diet grows, it  is  important that consumers
understand how to include them in a healthy diet without promoting weight gain. They
are high-fat,  energy dense foods and are therefore a  potential  threat  for  contributing to
positive energy balance. Numerous epidemiological and clinical studies have shown that
nuts are not associated with higher body weight [208, 209] or weight gain [210-215]. This
could be attributed along with other potential mechanisms for the high satiety properties
of nuts [216]. The enhanced satiety, which is also achieved via other mechanisms such as
the  decreased  eating  rate  [217],  leads  to  reduced  energy  consumption  and  therefore  a
decreased risk of weight gain and obesity.
Blomhoff et al. [190] argued that the inverse association between nut intake and cardiovascular
and coronary heart diseases in epidemiological studies may, or may not, be associated with
antioxidants. According to these authors, epidemiologic studies are not ideally suited for
studying the role of specific nuts or biological mechanisms. Nevertheless, they are in agree‐
ment with findings supporting the theory that a complex and rich mix of nut constituents is
able to offer protection against CVD and perhaps other chronic diseases [183].
2.2.5. Possible mechanism(s) of action
Epidemiologic and clinical trial evidence has demonstrated the beneficial effect of nut
consumption on coronary heart disease and its associated risk factors. The cardioprotective
properties of nuts, due partially to their favourable lipid fatty acid profile (rich in unsaturated
fatty acids), exceed the LDL-C lowering. Nuts, especially walnuts, contain (n-3) PUFAs, which
have been shown to have a favourable impact on multiple factors related to CVD, such as
inflammation, platelet function, arrhythmias, hypertriglyceridemia and nitric oxide-induced
endothelial relaxation [218]. Nuts are also excellent sources of other bioactive compounds such
as vegetable protein, dietary fibre, potassium, calcium, magnesium, tocopherols, phytosterols,
phenolic compounds, resveratrol and arginine [179]. This unique nutrient composition
explains the benefits of nut consumption for the prevention of CVD through mechanisms of
oxidation, inflammation and vascular reactivity.
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3. Conclusions and future directions
Investigation of the mechanisms underlying CVD showed that the disease has a complex cause
beyond the accumulation of cholesterol on the arterial wall, with enhanced oxidative stress
and a prominent inflammatory response. Diet has been shown to be associated with cardio‐
vascular events. PUFAs are essential in our diet because we cannot synthesize them. They are
also essential nutrients for optimal health of the cardiovascular, nervous and undoubtedly
other organ systems. Dietary (n-3) PUFAs are incorporated into the cellular membranes of all
tissues. The extent of incorporation into tissue membranes is dependent on dietary intake. The
enrichment of membranes with (n-3) PUFAs can modulate cellular signalling events, mem‐
brane protein function and gene expression.
Interest in the possible health benefits of flavonoids has increased owing to their potent
antioxidant and free-radical scavenging activities observed in vitro. There is growing evidence
from human feeding studies that the absorption and bioavailability of specific flavonoids is
much higher than originally believed. However, epidemiologic studies exploring the role of
flavonoids in human health have been inconclusive. Some studies support a protective effect
of flavonoid consumption in CVD and cancer; other studies demonstrate no effect and a few
studies suggest potential harm. More recently, results from human studies provide evidence
that rooibos can offer protection against oxidative stress conditions such as CVD [131,219]. In
a study by Pantsi et al., the beneficial effects of dietary rooibos flavonoids were observed ex
vivo in isolated perfused rat hearts. Epidemiological studies suggest that the beneficial
cardiovascular health effects of diets rich in fruit and vegetables are in part mediated by their
flavonoid content, with particular benefits provided by one member of this family, the
flavonols [49].
Polyphenols are abundant micronutrients in our diet and evidence for their role in the
prevention of degenerative diseases is emerging. Bioavailability differs greatly from one
polyphenol to another, so the most abundant polyphenols in our diet are not necessarily those
leading to the highest concentrations of active metabolites in target tissues. Because there are
many biological activities attributed to the flavonoids, some of which could be beneficial or
detrimental depending on specific circumstances, further studies in both the laboratory and
with populations are warranted.
However, the fatty acid components of nuts may differently influence oxidation processes and
this needs to be considered for the synergy or opposition to the effects of constituent antioxi‐
dants. There is growing evidence that dietary polyphenols in nuts, tea and wine may have
anti-inflammatory effects, mediated by both their antioxidant action and modulation of signal
transduction pathways, such as the nuclear transcription factor kB, with ensuing down-
regulation of inflammatory genes in endothelial cells and macrophages [220]. The increased
diversity and availability of sources of dietary fatty acids will likely allow the continued
expansion of food products fortified with these fatty acids, a trend that may result in the
attainment of the recommended dietary intake of these nutrients.
Future studies in oils should be carried out in order to elucidate the effects of oils in various
models in which effects remain unknown. Little is known about the effects of nuts on a diseased
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heart. Studies should be performed to test whether nuts may offer protection against the
severity or progression of various models of CVD.
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